BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 11, 2024
See today's BioWorld Asia
Home
» China's Bio-Thera launches phase III trial of HER2-positive breast cancer ADC candidate
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
China's Bio-Thera launches phase III trial of HER2-positive breast cancer ADC candidate
Nov. 14, 2018
By
Chermaine Lee
No Comments
HONG KONG – Chinese biologics and biosimilars maker Bio-Thera Solutions Ltd. kicked off a phase III trial of its HER2 antibody-drug conjugate (ADC), BAT-8001, targeting HER2-positive metastatic cancer.
BioWorld Asia
